BR112022022379A2 - Bioinformática - Google Patents

Bioinformática

Info

Publication number
BR112022022379A2
BR112022022379A2 BR112022022379A BR112022022379A BR112022022379A2 BR 112022022379 A2 BR112022022379 A2 BR 112022022379A2 BR 112022022379 A BR112022022379 A BR 112022022379A BR 112022022379 A BR112022022379 A BR 112022022379A BR 112022022379 A2 BR112022022379 A2 BR 112022022379A2
Authority
BR
Brazil
Prior art keywords
tumor antigen
cancer
bioinformatics
treatment
stratifying patients
Prior art date
Application number
BR112022022379A
Other languages
English (en)
Inventor
Cerullo Vincenzo
Capasso Cristian
Sikanen Tiina
Feola Sara
Tahka Sari
Chiaro Jacopo
Original Assignee
Univ Helsinki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Helsinki filed Critical Univ Helsinki
Publication of BR112022022379A2 publication Critical patent/BR112022022379A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/20—Screening of libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Evolutionary Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Library & Information Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)

Abstract

BIOINFORMÁTICA. A invenção se refere a um dispositivo para identificação de antígeno tumoral e um método para identificação de antígeno tumoral; um antígeno tumoral identificado após o uso do referido dispositivo e/ou método; uma composição farmacêutica compreendendo o referido antígeno tumoral; um método para tratar câncer usando o referido dispositivo e/ou o referido método; um método para estratificar pacientes para tratamento contra câncer usando o referido dispositivo e/ou o referido método; um regime de tratamento que envolve estratificar pacientes para tratamento contra câncer usando o referido dispositivo e/ou método e, em seguida, administrar um terapêutico contra câncer; e um antígeno tumoral identificado usando o referido dispositivo e/ou o referido método para uso como vacina contra câncer ou agente imunogênico ou terapia contra câncer.
BR112022022379A 2020-05-07 2021-05-06 Bioinformática BR112022022379A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2006760.9A GB202006760D0 (en) 2020-05-07 2020-05-07 Bioinformatics
PCT/EP2021/061981 WO2021224383A1 (en) 2020-05-07 2021-05-06 Bioinformatics

Publications (1)

Publication Number Publication Date
BR112022022379A2 true BR112022022379A2 (pt) 2022-12-13

Family

ID=71135048

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022379A BR112022022379A2 (pt) 2020-05-07 2021-05-06 Bioinformática

Country Status (11)

Country Link
US (1) US20230266307A1 (pt)
EP (1) EP4147047A1 (pt)
JP (1) JP2023529061A (pt)
KR (1) KR20230035233A (pt)
CN (1) CN115552245A (pt)
AU (1) AU2021268753A1 (pt)
BR (1) BR112022022379A2 (pt)
CA (1) CA3173171A1 (pt)
GB (1) GB202006760D0 (pt)
WO (1) WO2021224383A1 (pt)
ZA (1) ZA202210302B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024122719A1 (ko) * 2022-12-09 2024-06-13 (주)케어젠 연골 재생용 펩타이드 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964536B2 (en) * 2001-12-04 2011-06-21 Wayne State University Neoepitope detection of disease using protein arrays
WO2015177098A2 (en) 2014-05-19 2015-11-26 Helsingin Yliopisto Modified adenoviruses for cancer vaccines development
WO2017011660A1 (en) * 2015-07-14 2017-01-19 Personal Genome Diagnostics, Inc. Neoantigen analysis
WO2020236850A1 (en) * 2019-05-20 2020-11-26 Immunovalent Therapeutics Inc. Solid phase devices and methods of use for purifying and quantifying tissue-specific leukocytes
GB201907413D0 (en) * 2019-05-24 2019-07-10 Univ Helsinki Viral vector

Also Published As

Publication number Publication date
ZA202210302B (en) 2023-09-27
GB202006760D0 (en) 2020-06-24
US20230266307A1 (en) 2023-08-24
CA3173171A1 (en) 2021-11-11
EP4147047A1 (en) 2023-03-15
KR20230035233A (ko) 2023-03-13
CN115552245A (zh) 2022-12-30
JP2023529061A (ja) 2023-07-07
WO2021224383A1 (en) 2021-11-11
AU2021268753A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
MX2020009773A (es) Terapia de combinacion.
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
BR112016023025A2 (pt) direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3
BR112022015572A2 (pt) Anticorpo, composição, composição farmacêutica, anticorpo para uso como um medicamento, métodos para tratar uma doença e para produzir um anticorpo, ácido nucléico, um ou mais ácidos nucléicos, célula, e, kit de partes
MX2019003134A (es) Terapia de combinacion.
BR112022026888A2 (pt) Métodos de tratamento de câncer her2-positivo em um paciente, de terapia neoadjuvante de pacientes com câncer de mama inicial her2-positivo e de terapia neoadjuvante de câncer de mama inicial her2-positivo e método para tratar um paciente com câncer her2-positivo
BR112018074152A2 (pt) métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
BR112023002453A2 (pt) Composições de agente de via de estresse de replicação e métodos para tratar câncer
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112022022379A2 (pt) Bioinformática
BR112019011350A2 (pt) terapia de combinação
UY35250A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos.
BR112016023011A2 (pt) tratamento de câncer gástrico
BR112019006174A2 (pt) proteina terapêutica
MX2020013601A (es) Receptores de las celulas t especificos de cancer.
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r